Market Place
Sourcing Support
Rafael Pharma Announces Name Change to Cornerstone Pharmaceuticals, Inc.
19 May 2022 //
GLOBENEWSWIRE
Rafael Completes Enrollment in Phase 2 Trial of CPI-613 in biliary tract cancer
18 Jan 2022 //
GLOBENEWSWIRE
Rafael Pharma Completes Dose Escalation in APOLLO 613 Phase 1/2 Trial of CPI-613
06 Jan 2022 //
GLOBENEWSWIRE
Rafael resets after phase 3 flop, parting ways with 5 execs
24 Nov 2021 //
ROI-NJ
Rafael Begins Enrollment in Phase 1/2 Trial of CPI-613 in Clear Cell Sarcoma
11 Nov 2021 //
GLOBENEWSWIRE
Telecom tycoon`s phase 3 pancreatic cancer bet flames out
29 Oct 2021 //
MARKETWATCH
Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial
28 Oct 2021 //
GLOBENEWSWIRE
Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613®
27 Sep 2021 //
GLOBENEWSWIRE
Rafael Holdings Appoints Patrick Fabbio as Chief Financial Officer
14 Sep 2021 //
PRNEWSWIRE
Rafael Pharmaceuticals Initiates PII for CPI-613+Gemcitabine+Cisplatin in BTC
25 Aug 2021 //
GLOBENEWSWIRE
Rafael launches $104.2M private placement
20 Aug 2021 //
DAILYADVENT
Rafael Expands Team with Highly Experienced Global Biopharmaceutical Executives
17 Aug 2021 //
PRNEWSWIRE
Rafael Announces Positive Data on (ARMADA 2000) of CPI-613
01 Jul 2021 //
GLOBENEWSWIRE
Rafael Pharma to Present Pancreatic & Biliary Tract Cancer Data on CPI-613
30 Jun 2021 //
GLOBENEWSWIRE
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613
29 Jun 2021 //
GLOBENEWSWIRE
Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals
21 Jun 2021 //
PRNEWSWIRE
Rafael to Present New Pancreatic Cancer and Biliary Tract Cancer Data
26 May 2021 //
GLOBENEWSWIRE
Rafael to Present New Pancreatic Cancer and Biliary Tract Cancer Data CPI-613
26 May 2021 //
GLOBENEWSWIRE
Rafael Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial
30 Mar 2021 //
GLOBENEWSWIRE
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC
01 Dec 2020 //
GLOBENEWSWIRE
Rafael Receives FDA Fast Track Designation for CPI-613® (devimistat)
10 Nov 2020 //
GLOBENEWSWIRE
Rafael Crosses Enrollment of 100th Patient Ph3Trial (ARMADA 2000) of CPI-613®
27 Oct 2020 //
GLOBENEWSWIRE
A New Ph 1 Study Began to Evaluate Rafael Pharmaceuticals’ Lead Compound CPI-613
19 Oct 2020 //
YAHOO
Rafael Achieves Target Enrollment of 500 Patients in Ph 3 Trial (AVENGER 500)
06 Aug 2020 //
GLOBENEWSWIRE
Rafael Crosses Midpoint of Enrollment to First Interim Analysis Ph 3 Trial
21 Jul 2020 //
GLOBENEWSWIRE
Rafael to Present Phase 1 Data on CPI-613® (Devimistat) in Patients
26 May 2020 //
GLOBENEWSWIRE
Rafael Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat)
07 May 2020 //
GLOBENEWSWIRE
Generex Subsidiary NuGenerex Immuno-Oncology Announces AE37 Phase IIb
28 Apr 2020 //
GLOBENEWSWIRE
Rafael Receives Approvals to Open Trial Sites in India and Canada Ph3 Trial
23 Apr 2020 //
GLOBENEWSWIRE
Rafael Pharm Enrolls More Than 75% of Patients Needed for Ph3 (AVENGER 500)
24 Mar 2020 //
GLOBENEWSWIRE
